Mustang Bio, Inc (MBIO) reports that the U.S. Food and Drug Administration (FDA) has approved the Company’s investigational new dug application (IND) in acute myeloid leukemia (AML) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic...
CAR-T
Category
Expensive Cancer Drugs From Gilead and Novartis Losing Patients to Experimental Treatments
Large numbers of U.S. lymphoma patients are opting into experimental treatments in clinical trials versus expensive cell therapies sold by Gilead and Novartis, new data reveals, explaining why sales of the two products haven’t met rosy expectations. Reuters recently...
University of Zurich Grants Exclusive Worldwide License to Humanigen for the Prevention of GvHD through GM-CSF Neutralization
The University of Zurich has granted Humanigen an exclusive license for the prevention of GvHD (Graft-versus-Host Disease) through GM-CSF Neutralization. This deal helps Humanigen expand its extensive intellectual property portfolio to include prevention of...
Billionaire Controlled Biotech IND Approved For NK Cell Therapy to Enter Clinical Trials
NantKwest launches the first engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors. As reported in its press release, NantKwest established a leading...
Brigham and Women’s Hospital Study Neurological Side Effects of CAR T-cell Therapy
Science Daily reported that Brigham and Women's Hospital organized a team to catalog neurological symptoms of recent patient CAR T-cell therapy to better understand neurotoxic side effects. Of note, neurological symptoms were observed frequently (77% of patients...
Prostate Cancer Foundation Updates: Natural Killer Cells for Prostate Cancer
Investigators working with the Prostate Cancer Foundation, are harnessing the power of the immune system to treat cancer, including prostate cancer. Now, PCF funded investigator Dr. Aaron LeBeau, of the University of Minnesota and his team are developing a novel and...
Stanford Pre-Clinical Research Evidences CAR-T Cells a Potential Treatment for Pediatric Solid Tumors
Healio offers updates on Stanford University School of Medicine research via chimeric antigen receptor T cells targeting B7-H3 and attacking certain solid tumors in several pediatric cancer models. Stanford’s Robbie G. Majzner, MD said, “The treatment has yet to be...
USC Researcher Leads Promising Modified CART-T Cancer Therapy for Safer Results
In a small clinical study run in China, reports Stat News, patients were treated with a slightly modified version of an approved CAR-T saw benefits on par with pervious studies but with none of the well-known side effects that can hospitalize patients. If this...
Greek Investigator Seeks to Make CAR-T Far Cheaper than Novartis & Kite Pharma!
NeoCosmos reports a Greek assistant professor of medicine at the VUmc Cancer Centre in Amsterdam, Dr. Maria Themeli, is determined to make her patent for the treatment of blood cancer with the production of CAR-T cells freely available for all. First biopharma...
University of Pennsylvania Leads the Way for CAR T Patents
The University of Pennsylvania is the CAR T-cell research king of the United States. No institution in the country has filed for and been awarded as many patents as the Philadelphia-based institution. Penn and its scientists have filed for 428 patents for 54 separate...
Brighams and Women’s Hospital Researcher Slams Breaks on Lupus with CAR-T Cells
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periodic inflammatory flares in multiple organ systems and the formation of autoantibodies. The B cell–depleting anti-CD20 antibody Rituximab failed to improve lupus in two clinical...
Chinese Immune Cell Gene Therapy Start-up Secured $85 Million
Kenneth Lim of the Business Times reports that Suzhou China-based Gracell Biotechnologies has raised $85 million through a series B round led by Temasek Holdings—a Singapore government investment house. Other participants included Lilly Asia Ventures, Kington...
Two Diverging Worlds of CAR-T Cancer Fighters
Alex Lash writes in Xcomony that a generation ago, cancer treatments made from a patient’s own living immune cells would have been science fiction material. Today they are here. In fact, the first two products approved in 2017 and known as CAR-T, have brought some...
NCI Grants University of Pennsylvania $10.7 Million to Study CAR T-Cell Therapy for Solid Tumors
Healio reports that the National Cancer Institute (NCI) will grant $10.7 million to the University of Pennsylvania’s Abramson Cancer Center to evaluate the use of chimeric antigen receptor T-cell therapy for treatment of solid tumors. It is noted in Healio that...
University Hospitals Seidman Cancer Center CAR T-Cell Therapy for non-Hodgkin’s Lymphoma
An Ohio women reports that she is now cancer free following a CAR T-Cell therapy clinical trial being conducted at University Hospitals Seidman Cancer Center. According to a Fox News article written by Madeline Farber, Ohio-based Denise Keenan reports that ever since...
Celgene KarMMa Trial Phase 2 Myeloma for CAR T-cell Therapy Completes Enrollment
Patricia Inacio reports for Myeloma Research News that Celgene’s international Phase 2 trial testing investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment. The trial is...
CHOP Investigators Present Positive Updated Efficacy & Safety Data on Novartis’ Kymriah
As reported in PR Newswire, Children’s Hospital of Philadelphia (CHOP) investigators presented updated efficacy and safety data on Kymriah (tisagenlecleucel)—the first ever U.S FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the...
MD Anderson Reports 50%+ Survival Rate Post CAR-T Therapy for Diffuse Large B-Cell Lymphoma
The ZUMA-1 trial is sponsored by Kite Pharma (a Gilead Company) and was initiated to study the safety and efficacy of KTE-C19 in adults with refractory aggressive non-Hodgkin lymphoma. The study was co-led by The University of Texas, MD Anderson Cancer Center. A...
MD Anderson Real-World Outcomes of CAR-T Therapy As Standard of Care
As reported in the Journal of Clinical Pathways by Zachary Bessette, Ninety-day responses in the real world to chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory diffuse large B-cell lymphoma are comparable to the best responses...
Abramson Developing CAR T-Cell Therapy for Mesothelioma
As reported in Asbestos, the National Cancer Institute awarded a five-year, $10.7 million grant to Abramson Cancer Center at the University of Pennsylvania to develop CAR T-cell therapy for mesothelioma and lung cancer. Lead Research/Investigator Dr. Steven...